^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    quavonlimab (MK-1308)

    i
    Company:
    Akesobio, Merck (MSD)
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    Apply
    Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) (NCT03179436)
    Phase 1/2
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    04/16/2024
    Initiation :
    07/02/2017
    Primary completion :
    04/08/2024
    Completion :
    04/08/2024
    EGFR • BRAF • ALK • CTLA4
    |
    BRAF V600E • BRAF V600 • ALK translocation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • quavonlimab (MK-1308) • quavonlimab/pembrolizumab (MK-1308A)
    A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (KeyImPaCT) (NCT03516981)
    Phase 2
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    02/26/2024
    Initiation :
    10/01/2018
    Primary completion :
    06/28/2025
    Completion :
    06/28/2025
    EGFR • ALK • ROS1
    |
    ALK rearrangement
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • favezelimab (MK-4280) • quavonlimab (MK-1308) • favezelimab/pembrolizumab (MK-4280A)